𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impaired local natural killer cell activity in human colorectal carcinomas

✍ Scribed by Nieves M. Aparicio-Pagés; Hein W. Verspaget; Salvador A. Peña; Cornelis B. H. W. Lamers

Publisher
Springer-Verlag
Year
1989
Tongue
English
Weight
464 KB
Volume
28
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human renal-cell carcinoma cells are abl
Human renal-cell carcinoma cells are able to activate natural killer cells
✍ Kazuhiro Hayakawa; Tatsuo Morita; Lazel B. Augustus; Andrew C. von Eschenbach; K 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 French ⚖ 759 KB

## Abstract We previously reported that natural killer (NK) cells that had infiltrated renal‐cell carcinoma (RCC) proliferated vigorously in culture with interleukin‐2 (IL‐2) and lysed autologous tumor cells. In this study, we investigate the susceptibility of RCC cells to NK‐cell lysis and their a

The prognostic significance of intratumo
The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma
✍ Santiago Coca; Javier Perez-Piqueras; David Martinez; Antonio Colmenarejo; Migue 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 824 KB

## Background: Natural killer (nk) cells have a spontaneous cytotoxic capacity-against tumor cells. these cells represent a small proportion of human colon carcinoma-infiltrating lymphocytes. their prognostic significance in these tumors has yet to be determined. ## Methods: One hundred and fifty

Adverse effects of intraportal chemother
Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients
✍ Rafique, Mohammad; Adachi, Wataru; Koike, Shoichiro; Kajikawa, Shoji; Yazawa, Ka 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 2 views

## Background: Adjuvant intraportal chemotherapy has been used with a view to prevent the development of metachronous hepatic metastases following curative resection for colorectal cancer. to evaluate the effects of this therapy on systemic antitumor immunological activity, 35 colorectal cancer pat